Characterization of long-acting beta2-adrenergic agonists utilization in asthma patients

Journal of Asthma

Volumn 49, Issue 10, 2012, Pages 1079-1085

  Kaplan, Sigal ^a   Zhou, Esther H ^a   Iyasu, Solomon ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Asthma; Drug concurrency; Drug use; Fixed dose combination LABAs; Long acting beta2 adrenergic agonists; Single ingredient LABAs

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMONE DERIVATIVE; IMMUNOMODULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLXANTHINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; COMBINATION CHEMOTHERAPY; DRUG MONITORING; DRUG SAFETY; DRUG UTILIZATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRESCRIPTION; SCHOOL CHILD; TREATMENT DURATION;

ADOLESCENT; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; INFANT; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; YOUNG ADULT;

EID: 84874181414     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2012.733990     Document Type: Article

References (20)

1. Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting betaagonists in the treatment of asthma. N Engl J Med 2010; 362,(13): 1169-1171
2. McMahon AW, Levenson MS,McEvoy BW, Mosholder AD,Murphy D. Age and risks of FDA-approved long-acting β2-Adrenergic receptor agonists. Pediatrics 2011; 128,(5):e1147-e1154
3. FDA Drug Safety Communication: New safety requirements for longacting inhaled asthma medications called long-acting beta-agonists, (LABAs). 18 February 2010. Available at: Http://www.fda.gov/Drugs/ DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm200776.htm?sms- ssemail. Accessed February 8, 2012
4. FDA Drug Safety Communication: Drug labels now contain updated recommendations on the appropriate use of long-acting inhaled asthma medications called long-acting beta-agonists, (LABAs). 2 June 2010. Available at: Http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug SafetyInformationforPatientsandProviders/ucm213836.htm. Accessed February 8, 2012
5. ADVAIR® DISKUS®, (fluticasone propionate and salmeterol inhalation powder): Prescribing information. GlaxoSmithKline 2006; Available at: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/021077s 026lbl.pdf. Accessed February 8, 2012
6. SEREVENT® DISKUS®, (salmeterol xinafoate inhalation powder): Prescribing information. GlaxoSmithKline 2006; Available at: Http:// www.accessdata.fda.gov/drugsatfda-docs/label/2006/020692s029lbl. pdf. Accessed February 8, 2012
7. BROVANA™,(arformoterol tartrate Inhalation Solution): Prescribing information. Sepracor Inc 2006; Available at: Http://www.accessdata.fda.gov/ drugsatfda-docs/label/2006/021912lbl.pdf. Accessed February 8, 2012
8. SYMBICORT®, (budesonide and formoterol fumarate Inhalation Aerosol): Prescribing information. AstraZeneca 2006; Available at: Http://www.accessdata. fda.gov/drugsatfda-docs/label/2006/021929lbl. pdf. Accessed February 8, 2012
9. FORADIL® AEROLIZER®, (formoterol fumarate inhalation powder): Prescribing Information. Novartis AG 2006; Available at: Http://www. accessdata.fda.gov/drugsatfda-docs/label/2006/020831s009lbl.pdf. Accessed February 8, 2012
10. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health; National Heart, Lung, and Blood Institute. NIH publication no. 07-4051. Available at: Http://www. nhlbi.nih.gov/guidelines/asthma/ asthgdln.pdf. Accessed August 28, 2007
11. Friedman H, Wilcox T, Reardon G, Crespi S, Yawn BP. A retrospective study of the use of fluticasone propionate/salmeterol combination as initial asthma controller therapy in a commercially insured population. Clin Ther 2008; 30:1908-1917
12. Stempel DA, Stoloff SW, Carranza Rosenzweig JR, Stanford RH, Ryskina KL, Legorreta AP. Adherence to asthma controller medication regimens. Respir Med 2005; 99,(10):1263-1267 (Pubitemid 41245312)
13. Blanchette CM, Culler SD, Ershoff D, Gutierrez B. Association between previous health care use and initiation of inhaled corticosteroid and longacting beta2-adrenergic agonist combination therapy among US patients with asthma. Clin Ther 2009; 31:2574-2583
14. Ye X, Gutierrez B, Zarotsky V, Nelson M, Blanchette CM. Appropriate use of inhaled corticosteroid and long-acting beta,(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population. Curr Med Res Opin 2009; 25:2251-2258
15. Tan H, Sarawate C, Singer J, Elward K, Cohen RI, Smart BA, Busk MF, Lustig J, O'Brien JD, Schatz M. Impact of asthma controller medications on clinical, economic, and patient-reported outcomes. Mayo Clin Proc 2009; 84:675-684
16. Stephenson JJ, Quimbo RA, Gutierrez B. Subacute lack of asthma control as a predictor of subsequent acute asthma exacerbation in a managed care population. Am J Manag Care 2010; 16:108-114
17. Broder MS, Chang EY, Kamath T, Sapra S. Poor disease control among insured users of high-dose combination therapy for asthma. Allergy Asthma Proc 2010; 31:60-67
18. Cooper WO, Hickson GB. Corticosteroid prescription filling for children covered by Medicaid following an emergency department visit or a hospitalization for asthma. Arch Pediatr AdolescMed 2001; 155:1111-1115 (Pubitemid 32917194)
19. Friedman HS, Eid NS, Crespi S, Wilcox TK, Reardon G. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations. Clin Ther 2009; 31:1056-1063
20. Beauchesne MF, Chartier A, Fillion A, Lemière C, Lecompte S, Blais L. Asthma control score based on filled medication prescriptions: A validation study. Can Respir J 2008; 15:423-426